Ionis Pharmaceuticals, Inc.
corporate_fare Company Profile
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 43 items for IONS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for IONS spans 10-Q, 8-K.
Recent high-impact activity:
- Diranersen Slows Alzheimer's Decline Further at Two Years, 38% on CDR-SB
- EU Regulators Grant TRYNGOLZA Broader Approval in Severe Hypertriglyceridemia
- Ionis Cuts TRYNGOLZA 2026 Guidance to ~$50M as Q3 Loss Widens
- Ionis Slashes 2026 Tryngolza Guidance, Shares Sink Toward 52-Week Low
- Ionis Q3: Revenue $242.7M, Net Loss $110.0M; TRYNGOLZA Guidance Cut and Pelacarsen Royalty Write-Down
Financial Snapshot
Short Interest & Short Volume
8.41 days to coverFINRA reported short interest of 21,165,846 shares in IONS as of the October 30, 2026 settlement, a 2.5% increase from the prior period — about 8.4 days to cover at its recent average daily volume. On November 20, 2026, 50.0% of IONS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.